Wnt signaling in liver regeneration, disease, and cancer

키워드

참고문헌 (176)

1. Clemens MM, "Mechanisms and biomarkers of liver regeneration after drug-induced liver injury", Adv Pharmacol, 85, pp.241~262 (2019)
2. Michalopoulos GK, "Hepatostat : liver regeneration and normal liver tissue maintenance", Hepatology, 65, pp.1384~1392 (2017)
3. Ko S, "Liver progenitors and adult cell plasticity in hepatic injury and repair : knowns and unknowns", Annu Rev Pathol, 15, pp.23~50 (2020)
4. Duncan AW, "The ploidy conveyor of mature hepatocytes as a source of genetic variation", Nature, 467, pp.707~710 (2010)
5. Anti M, "DNA ploidy pattern in human chronic liver diseases and hepatic nodular lesions. Flow cytometric analysis on echoguided needle liver biopsy", Cancer, 73, pp.281~288 (1994)
6. Duncan AW, "Frequent aneuploidy among normal human hepatocytes", Gastroenterology, 142, pp.25~28 (2012)
7. Siegel RL, "Cancer statistics, 2022", CA Cancer J Clin, 72, pp.7~33 (2022)
8. Llovet JM, "Hepatocellular carcinoma", Nat Rev Dis Primers, 2, pp.16018~ (2016)
9. Tortelote GG, "Complexity of the Wnt", β‑catenin pathway : searching for an activation model, 2017, pp.40, 30~43
10. Xia XH, "Facilitation of liver cancer SMCC7721cell aging by sirtuin 4 via inhibiting JAK2", STAT3 signal pathway, 2017, pp.21, 1248~1253
11. Chen J, "Immunomodulatory TGF-βsignaling in hepatocellular carcinoma", Trends Mol Med, 25, pp.1010~1023 (2019)
12. Czauderna C, "Contextdependent role of NF-κB signaling in primary liver cancerfrom tumor development to therapeutic implications", Cancers(Basel), 11, pp.1053~ (2019)
13. Russell JO, "Wnt", β-catenin signaling in liver development, homeostasis, and pathobiology, 2018, pp.13, 351~378
14. Cheng JH, "Wnt antagonism inhibits hepatic stellate cell activation and liver fibrosis", Am J Physiol Gastrointest Liver Physiol, 294, pp.G39~G49 (2008)
15. Zeng G, "Wnt’er in liver : expression of Wnt and frizzled genes in mouse", Hepatology, 45, pp.195~204 (2007)
16. Ma R, "Metabolic and non-metabolic liver zonation is established non-synchronously and requires sinusoidal Wnts", Elife, 9, pp.e46206~ (2020)
17. Monga SP, "β-catenin signaling and roles in liver homeostasis, injury, and tumorigenesis", Gastroenterology, 148, pp.1294~1310 (2015)
18. Nusse R, "Wnt", β-catenin signaling, disease, and emerging therapeutic modalities, 2017, pp.169, 985~999
19. Clevers H, "Wnt", β-catenin signaling and disease, 2012, pp.149, 1192~1205
20. Scheibner K, "Wnt signaling : implications in endoderm development and pancreas organogenesis", Curr Opin Cell Biol, 61, pp.48~55 (2019)
21. Steinhart Z, "Wnt signaling in development and tissue homeostasis", Development, 145, pp.dev146589~ (2018)
22. Hu S, "Wnt", -catenin signaling and liver regeneration : circuit, biology, and opportunities, 2021, pp.20, 189~199
23. Zhan T, "Wnt signaling in cancer", Oncogene, 36, pp.1461~1473 (2017)
24. Ahmed A. Raslan, "WNT Signaling in Lung Repair and Regeneration", Molecules and Cells, 43(9), pp.774~783 (2020), 한국분자세포생물학회[DOI]
25. Girardi F, "Wnt signaling in skeletal muscle development and regeneration", Prog Mol Biol Transl Sci, 153, pp.157~179 (2018)
26. Jackstadt R, "WNT and β-catenin in cancer : genes and therapy", Annu Rev Cancer Biol, 4, pp.177~196 (2020)
27. Monga SP, "Changes in WNT", beta-catenin pathway during regulated growth in rat liver regeneration, 2001, pp.33, 1098~1109
28. Stolz DB, "Growth factor signal transduction immediately after two-thirds partial hepatectomy in the rat", Cancer Res, 59, pp.3954~3960 (1999)
29. Köhler C, "Expression of notch-1 and its ligand Jagged-1 in rat liver during liver regeneration", Hepatology, 39, pp.1056~1065 (2004)
30. Higgins GM, "Experimental pathology of the liver. 1. Restoration of the liver of the white rat following partial surgical removal", Arch Pathol, 12, pp.186~202 (1931)
31. Nikfarjam M, "A model of partial hepatectomy in mice", J Invest Surg, 17, pp.291~294 (2004)
32. Sadler KC, "Liver growth in the embryo and during liver regeneration in zebrafish requires the cell cycle regulator, uhrf1", Proc Natl Acad Sci U S A, 104, pp.1570~1575 (2007)
33. Curado S, "Nitroreductase-mediated cell", tissue ablation in zebrafish : a spatially and temporally controlled ablation method with applications in developmental and regeneration studies, 2008, pp.3, 948~954
34. Teschke R, "Carbon tetrachloride(CCl4)levels and serum activities of liver enzymes following acute CCl4 intoxication", Toxicol Lett, 17, pp.175~180 (1983)
35. Preisegger KH, "Atypical ductular proliferation and its inhibition by transforming growth factor beta1 in the 3, 5-diethoxycarbonyl-1, 4-dihydrocollidine mouse model for chronic alcoholic liver disease", Lab Invest, 79, pp.103~109 (1999)
36. Oderberg IM, "Partial hepatectomy in adult zebrafish", J Vis Exp, (170) (2021)[DOI]
37. North TE, "PGE2-regulated Wnt signaling and N-acetylcysteine are synergistically hepatoprotective in zebrafish acetaminophen injury", Proc Natl Acad Sci U S A, 107, pp.17315~17320 (2010)
38. Sekine S, "Liver-specific loss of beta-catenin results in delayed hepatocyte proliferation after partial hepatectomy", Hepatology, 45, pp.361~368 (2007)
39. Goessling W, "APC mutant zebrafish uncover a changing temporal requirement for wnt signaling in liver development", Dev Biol, 320, pp.161~174 (2008)
40. Sun T, "AXIN2+ pericentral hepatocytes have limited contributions to liver homeostasis and regeneration", Cell Stem Cell, 26, pp.97~107 (2020)
41. Huch M, "In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration", Nature, 494, pp.247~250 (2013)
42. Carmon KS, "LGR5 interacts and cointernalizes with Wnt receptors to modulate Wnt", β-catenin signaling, 2012, pp.32, 2054~2064
43. Jho EH, "Wnt", beta-catenin, Mol Cell Biol, pp.2002, 22[DOI]
44. Lustig B, "Negative feedback loop of Wnt signaling through upregulation of conductin", axin2 in colorectal and liver tumors, 2002, pp.22, 1184~1193
45. Jung YS, "TMEM9 promotes intestinal tumorigenesis through vacuolar-ATPase-activated Wnt", β-catenin signalling, 2018, pp.20, 1421~1433
46. Jung YS, "TMEM9-v-ATPase activates Wnt", β-catenin signaling via APC lysosomal degradation for liver regeneration and tumorigenesis, 2021, pp.73, 776~794
47. Kudo Y, "PKCλ", ι loss induces autophagy, oxidative phosphorylation, and NRF2 to promote liver cancer progression, 2020, pp.38, 247~262
48. Wang Z, "Oxidative stress and liver cancer : etiology and therapeutic targets", Oxid Med Cell Longev, 2016, pp.7891574~ (2016)
49. Funato Y, "The thioredoxinrelated redox-regulating protein nucleoredoxin inhibits Wntbeta-catenin signalling through dishevelled", Nat Cell Biol, 8, pp.501~508 (2006)
50. Zhou T, "The role of lipid peroxidation products and oxidative stress in activation of the canonical wingless-type MMTV integration site(WNT)pathway in a rat model of diabetic retinopathy", Diabetologia, 54, pp.459~468 (2011)
51. Sun HC, "Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma", J Hepatol, 47, pp.684~690 (2007)
52. Rein DB, "Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States", Dig Liver Dis, 43, pp.66~72 (2011)
53. Yang JD, "Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma", Clin Gastroenterol Hepatol, 9, pp.64~70 (2011)
54. Roudot-Thoraval F, "Epidemiology of hepatitis C virus infection", Clin Res Hepatol Gastroenterol, 45, pp.101596~ (2021)
55. Mavilia MG, "HBV-HCV coinfection : viral interactions, management, and viral reactivation", J Clin Transl Hepatol, 6, pp.296~305 (2018)
56. Levrero M, "Mechanisms of HBV-induced hepatocellular carcinoma", J Hepatol, 64(1 Suppl), pp.S84~S101 (2016)
57. Arbuthnot P, "Hepatitis B virus and hepatocellular carcinoma", Int J Exp Pathol, 82, pp.77~100 (2001)
58. Neuveut C, "Mechanisms of HBV-related hepatocarcinogenesis", J Hepatol, 52, pp.594~604 (2010)
59. Tian X, "Role of hepatitis B surface antigen in the development of hepatocellular carcinoma : regulation of lymphoid enhancer-binding factor 1", J Exp Clin Cancer Res, 28, pp.58~ (2009)
60. Javanmard D, "Investigation of CTNNB1 gene mutations and expression in hepatocellular carcinoma and cirrhosis in association with hepatitis B virus infection", Infect Agent Cancer, 15, pp.37~ (2020)
61. Zucman-Rossi J, "Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas", Oncogene, 26, pp.774~780 (2007)
62. Galy O, "Mutations in TP53 and CTNNB1 in relation to hepatitis B and C infections in hepatocellular carcinomas from Thailand", Hepat Res Treat, 2011, pp.697162~ (2011)
63. Hsieh A, "Hepatitis B viral X protein interacts with tumor suppressor adenomatous polyposis coli to activate Wnt", β-catenin signaling, 2011, pp.300, 162~172
64. Feitelson MA, "Hepatitis B virus X antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma", Am J Pathol, 150, pp.1141~1157 (1997)
65. Lau CC, "Viralhuman chimeric transcript predisposes risk to liver cancer development and progression", Cancer Cell, 25, pp.335~349 (2014)
66. Moradpour D, "Hepatitis C virus proteins : from structure to function", Curr Top Microbiol Immunol, 369, pp.113~142 (2013)
67. Fukutomi T, "Hepatitis C virus core protein stimulates hepatocyte growth : correlation with upregulation of Wnt-1 expression", Hepatology, 41, pp.1096~1105 (2005)
68. Liu J, "Enhancement of canonical Wnt", β-catenin signaling activity by HCV core protein promotes cell growth of hepatocellular carcinoma cells, 2011, pp.6, e27496~
69. Umer M, "Promoter hypermethylation of Wnt pathway inhibitors in hepatitis C virus-induced multistep hepatocarcinogenesis", Virol J, 11, pp.117~ (2014)
70. Quan H, "Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition", Oncogene, 33, pp.2826~2835 (2014)
71. Ripoli M, "Hypermethylated levels of E-cadherin promoter in Huh-7 cells expressing the HCV core protein", Virus Res, 160, pp.74~81 (2011)
72. Jung YS, "Deregulation of CRAD-controlled cytoskeleton initiates mucinous colorectal cancer via β-catenin", Nat Cell Biol, 20, pp.1303~1314 (2018)
73. Liu Y, "WNT signaling pathway gene polymorphisms and risk of hepatic fibrosis and inflammation in HCV-infected patients", PLoS One, 8, pp.e84407~ (2013)
74. Takahara Y, "Serial changes in expression of functionally clustered genes in progression of liver fibrosis in hepatitis C patients", World J Gastroenterol, 14, pp.2010~2022 (2008)
75. Mercer KE, "Alcohol consumption, Wnt", β-catenin signaling, and hepatocarcinogenesis, 2015, pp.815, 185~195
76. 김한상, "The p90rsk-mediated signaling of ethanol-induced cell proliferation in HepG2 cell line", The Korean Journal of Physiology & Pharmacology, 20(6), pp.595~603 (2016), 대한약리학회
77. Wang F, "Activation of the NF-κB pathway as a mechanism of alcohol enhanced progression and metastasis of human hepatocellular carcinoma", Mol Cancer, 14, pp.10~ (2015)
78. Yang CF, "NOX4", ROS mediate ethanol‑induced apoptosis via MAPK signal pathway in L‑02 cells, 2018, pp.41, 2306~2316
79. Zhang C, "Inhibition of vascular endothelial growth factor signaling facilitates liver repair from acute ethanol-induced injury in zebrafish", Dis Model Mech, 9, pp.1383~1396 (2016)
80. Mandrekar P, "An essential role for monocyte chemoattractant protein-1 in alcoholic liver injury : regulation of proinflammatory cytokines and hepatic steatosis in mice", Hepatology, 54, pp.2185~2197 (2011)
81. Yuen MF, "Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B", J Hepatol, 50, pp.80~88 (2009)
82. Wong VW, "Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese : a population study using proton-magnetic resonance spectroscopy and transient elastography", Gut, 61, pp.409~415 (2012)
83. Bhala N, "The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis : an international collaborative study", Hepatology, 54, pp.1208~1216 (2011)
84. Geoffrey C. Farrell, "NASH is an Infl ammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications", Gut and Liver, 6(2), pp.149~171 (2012), 거트앤리버 소화기연관학회협의회[DOI]
85. Murphy SK, "Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease", Gastroenterology, 145, pp.1076~1087 (2013)
86. Chettouh H, "Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma", Liver Int, 35, pp.2203~2217 (2015)
87. Jonatan D, "Sox17 regulates insulin secretion in the normal and pathologic mouse β cell", PLoS One, 9, pp.e104675~ (2014)
88. Jia Y, "SOX17 antagonizes WNT", β-catenin signaling pathway in hepatocellular carcinoma, 2010, pp.5, 743~749
89. Ackers I, "Interrelationship of canonical and noncanonical Wnt signalling pathways in chronic metabolic diseases", Diab Vasc Dis Res, 15, pp.3~13 (2018)
90. Wang S, "Nonalcoholic fatty liver disease induced by noncanonical Wnt and its rescue by Wnt3a", FASEB J, 29, pp.3436~3445 (2015)
91. Kew MC, "Synergistic interaction between aflatoxin B1and hepatitis B virus in hepatocarcinogenesis", Liver Int, 23, pp.405~409 (2003)
92. Devereux TR, "CTNNB1 mutations and beta-catenin protein accumulation in human hepatocellular carcinomas associated with high exposure to aflatoxin B1", Mol Carcinog, 31, pp.68~73 (2001)
93. Yang JD, "A global view of hepatocellular carcinoma : trends, risk, prevention and management", Nat Rev Gastroenterol Hepatol, 16, pp.589~604 (2019)
94. Bengochea A, "Common dysregulation of Wnt", frizzled receptor elements in human hepatocellular carcinoma, 2008, pp.99, 143~150
95. Boyault S, "Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets", Hepatology, 45, pp.42~52 (2007)
96. Fodde R, "APC, signal transduction and genetic instability in colorectal cancer", Nat Rev Cancer, 1, pp.55~67 (2001)
97. Khemlina G, "The biology of hepatocellular carcinoma : implications for genomic and immune therapies", Mol Cancer, 16, pp.149~ (2017)
98. Satoh S, "AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1", Nat Genet, 24, pp.245~250 (2000)
99. Park JY, "Mutations of beta-catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis", Liver Int, 25, pp.70~76 (2005)
100. Zhu M, "Somatic mutations increase hepatic clonal fitness and regeneration in chronic liver disease", Cell, 177, pp.608~621 (2019)
101. Marquardt JU, "Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits", J Hepatol, 60, pp.346~353 (2014)
102. Rebouissou S, "Advances in molecular classification and precision oncology in hepatocellular carcinoma", J Hepatol, 72, pp.215~229 (2020)
103. Abitbol S, "AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation", J Hepatol, 68, pp.1203~1213 (2018)
104. Lazaridis KN, "Zakim and Boyer’s Hepatology", pp.1032~1044 (2012), Saunders
105. Boulter L, "WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited", J Clin Invest, 125, pp.1269~1285 (2015)
106. Chen W, "Characterizing the activation of the Wnt signaling pathway in hilar cholangiocarcinoma using a tissue microarray approach", Eur J Histochem, 60, pp.2536~ (2016)
107. Banales JM, "Cholangiocarcinoma 2020 : the next horizon in mechanisms and management", Nat Rev Gastroenterol Hepatol, 17, pp.557~588 (2020)
108. Vaquero J, "Epithelial-mesenchymal transition in cholangiocarcinoma : from clinical evidence to regulatory networks", J Hepatol, 66, pp.424~441 (2017)
109. Nitta T, "Prognostic significance of epithelialmesenchymal transition-related markers in extrahepatic cholangiocarcinoma : comprehensive immunohistochemical study using a tissue microarray", Br J Cancer, 111, pp.1363~1372 (2014)
110. Chaw SY, "Epithelial to mesenchymal transition(EMT)biomarkers--E-cadherin, beta-catenin, APC and vimentin--in oral squamous cell carcinogenesis and transformation", Oral Oncol, 48, pp.997~1006 (2012)
111. Valenta T, "The many faces and functions of β-catenin", EMBO J, 31, pp.2714~2736 (2012)
112. Zhang GF, "Wnt", β-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma, 2020, pp.40, BSR20193353~
113. Xue W, "Upregulation of TTYH3 promotes epithelial-to-mesenchymal transition through Wnt", β-catenin signaling and inhibits apoptosis in cholangiocarcinoma, 2021, pp.44, 1351~1361
114. Carrillo-Reixach J, "Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications", J Hepatol, 73, pp.328~341 (2020)
115. Gupta K, "Relationship of β-catenin and postchemotherapy histopathologic changes with overall survival in patients with hepatoblastoma", J Pediatr Hematol Oncol, 34, pp.e320~e328 (2012)
116. Crippa S, "Mutant CTNNB1 and histological heterogeneity define metabolic subtypes of hepatoblastoma", EMBO Mol Med, 9, pp.1589~1604 (2017)
117. López-Terrada D, "Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and notch pathway activation in DLK+ precursors", Hum Pathol, 40, pp.783~794 (2009)
118. Taniguchi K, "Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas", Oncogene, 21, pp.4863~4871 (2002)
119. Shah K, "Porcupine inhibitors : novel and emerging anti-cancer therapeutics targeting the Wnt signaling pathway", Pharmacol Res, 167, pp.105532~ (2021)
120. Liu J, "Targeting Wnt-driven cancer through the inhibition of porcupine by LGK974", Proc Natl Acad Sci U S A, 110, pp.20224~20229 (2013)
121. Madan B, "Wnt addiction of genetically defined cancers reversed by PORCN inhibition", Oncogene, 35, pp.2197~2207 (2016)
122. Proffitt KD, "Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer", Cancer Res, 73, pp.502~507 (2013)
123. Wang W, "Blocking Wnt secretion reduces growth of hepatocellular carcinoma cell lines mostly independent of β-catenin signaling", Neoplasia, 18, pp.711~723 (2016)
124. Barrott JJ, "Deletion of mouse porcn blocks Wnt ligand secretion and reveals an ectodermal etiology of human focal dermal hypoplasia", Goltz syndrome, 2011, pp.108, 12752~12757
125. Liu W, "Deletion of porcn in mice leads to multiple developmental defects and models human focal dermal hypoplasia(Goltz syndrome)", PLoS One, 7, pp.e32331~ (2012)
126. Funck-Brentano T, "Porcupine inhibitors impair trabecular and cortical bone mass and strength in mice", J Endocrinol, 238, pp.13~23 (2018)
127. He X, "LDL receptor-related proteins 5 and 6 in Wnt", beta-catenin signaling : arrows point the way, 2004, pp.131, 1663~1677
128. Wei W, "Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells", Mol Cancer, 8, pp.76~ (2009)
129. Cruciat CM, "Secreted and transmembrane wnt inhibitors and activators", Cold Spring Harb Perspect Biol, 5, pp.a015081~ (2013)
130. Niehrs C, "Function and biological roles of the Dickkopf family of Wnt modulators", Oncogene, 25, pp.7469~7481 (2006)
131. Kawazoe M, "Glucocorticoid therapy suppresses Wnt signaling by reducing the ratio of serum Wnt3a to Wnt inhibitors, sFRP-1 and Wif-1", Clin Rheumatol, 40, pp.2947~2954 (2021)
132. Hu J, "Blockade of Wnt signaling inhibits angiogenesis and tumor growth in hepatocellular carcinoma", Cancer Res, 69, pp.6951~6959 (2009)
133. Glinka A, "Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction", Nature, 391, pp.357~362 (1998)
134. Caneparo L, "Dickkopf-1 regulates gastrulation movements by coordinated modulation of Wnt", beta catenin and Wnt, Genes Dev, pp.2007, 21[DOI]
135. Cha SW, "Wnt5a and Wnt11 interact in a maternal Dkk1-regulated fashion to activate both canonical and non-canonical signaling in Xenopus axis formation", Development, 135, pp.3719~3729 (2008)
136. Nambotin SB, "Pharmacological inhibition of frizzled-7 displays anti-tumor properties in hepatocellular carcinoma", J Hepatol, 54, pp.288~299 (2011)
137. Jimeno A, "A first-in-human phase I study of the anticancer stem cell agent ipafricept(OMP-54F28), a decoy receptor for wnt ligands, in patients with advanced solid tumors", Clin Cancer Res, 23, pp.7490~7497 (2017)
138. Moore KN, "A phase 1b dose escalation study of ipafricept(OMP54F28)in combination with paclitaxel and carboplatin in patients with recurrent platinumsensitive ovarian cancer", Gynecol Oncol, 154, pp.294~301 (2019)
139. Hoey T, "Development of FZD8-Fc (OMP-54F28), a Wnt signaling antagonist that inhibits tumor growth and reduces tumor initiating cell frequency", AACR Annual Meeting (2013)
140. Wei W, "Soluble frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin", Mol Cancer, 10, pp.16~ (2011)
141. Fischer MM, "WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death", Sci Adv, 3, pp.e1700090~ (2017)
142. Gurney A, "Wnt pathway inhibition via the targeting of frizzled receptors results in decreased growth and tumorigenicity of human tumors", Proc Natl Acad Sci U S A, 109, pp.11717~11722 (2012)
143. Davis SL, "A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer", Invest New Drugs, 38, pp.821~830 (2020)
144. Smith DC, "First-in-human evaluation of the human monoclonal antibody vantictumab(OMP-18R5; antiFrizzled)targeting the WNT pathway in a phase I study for patients with advanced solid tumors", J Clin Oncol, 31(suppl), pp.2540a~ (2013)
145. Gupta PB, "Identification of selective inhibitors of cancer stem cells by high-throughput screening", Cell, 138, pp.645~659 (2009)
146. Huczynski A, "Salinomycin : a new cancer drug candidate", Chem Biol Drug Des, 79, pp.235~238 (2012)
147. Lu D, "Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells", Proc Natl Acad Sci U S A, 108, pp.13253~13257 (2011)
148. Niwa AM, "Salinomycin induces cell cycle arrest and apoptosis and modulates hepatic cytochrome P450mRNA expression in HepG2", C3a cells, 2022, pp.32, 341~351
149. Liu Q, "Salinomycin suppresses tumorigenicity of liver cancer stem cells and Wnt", beta-catenin signaling, 2021, pp.16, 630~637
150. Huang SM, "Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling", Nature, 461, pp.614~620 (2009)
151. Clevers H, "Wnt", beta-catenin signaling in development and disease, 2006, pp.127, 469~480
152. Rubinfeld B, "Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly", Science, 272, pp.1023~1026 (1996)
153. Ma Y, "Dihydroartemisinin suppresses proliferation, migration, the Wnt", β-catenin pathway and EMT via TNKS in gastric cancer, 2021, pp.22, 688~
154. Ma Z, "circ5615 functions as a ceRNA to promote colorectal cancer progression by upregulating TNKS", Cell Death Dis, 11, pp.356~ (2020)
155. Ma L, "Tankyrase inhibitors attenuate WNT", β-catenin signaling and inhibit growth of hepatocellular carcinoma cells, 2015, pp.6, 25390~25401
156. Wu X, "Tankyrase 1 inhibitior XAV939 increases chemosensitivity in colon cancer cell lines via inhibition of the Wnt signaling pathway", Int J Oncol, 48, pp.1333~1340 (2016)
157. Huang J, "Tankyrases", β-catenin signaling pathway as an anti-proliferation and anti-metastatic target in hepatocarcinoma cell lines, 2020, pp.11, 432~440
158. Ghany MG, "Diagnosis, management, and treatment of hepatitis C : an update", Hepatology, 49, pp.1335~1374 (2009)
159. Lee D, "Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1-positive hepatocellular carcinoma", Cancer, 119, pp.2239~2246 (2013)
160. Thompson MD, "Pegylated interferon alpha targets Wnt signaling by inducing nuclear export of β-catenin", J Hepatol, 54, pp.506~512 (2011)
161. Deng J, "The CREB-binding protein inhibitor ICG-001 : a promising therapeutic strategy in sporadic meningioma with NF2 mutations", Neurooncol Adv, 2, pp.vdz055~ (2020)
162. Takahashi-Yanaga F, "Targeting Wnt signaling : can we safely eradicate cancer stem cells?", Clin Cancer Res, 16, pp.3153~3162 (2010)
163. Delgado ER, "Identification and characterization of a novel smallmolecule inhibitor of β-catenin signaling", Am J Pathol, 184, pp.2111~2122 (2014)
164. Wei W, "Small molecule antagonists of Tcf4", beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo, 2010, pp.126, 2426~2436
165. Gedaly R, "Targeting the Wnt", β-catenin signaling pathway in liver cancer stem cells and hepatocellular carcinoma cell lines with FH535, 2014, pp.9, e99272~
166. Handeli S, "A small-molecule inhibitor of Tcf", beta-catenin signaling down-regulates PPARgamma and PPARdelta activities, 2008, pp.7, 521~529
167. Gwak J, "Small moleculebased promotion of PKCα-mediated β-catenin degradation suppresses the proliferation of CRT-positive cancer cells", PLoS One, 7, pp.e46697~ (2012)
168. Chen X, "Wnt signaling: the good and the bad", Acta Biochim Biophys Sin(Shanghai), 40, pp.577~594 (2008)
169. Chen D, "Wnt signaling in bone, kidney, intestine, and adipose tissue and interorgan interaction in aging", Ann N Y Acad Sci, 1442, pp.48~60 (2019)
170. Behari J, "The Wnt", β-catenin signaling pathway in liver biology and disease, 2010, pp.4, 745~756
171. Bowman EJ, "The bafilomycin", concanamycin binding site in subunit c of the v-ATPases from Neurospora crassa and Saccharomyces cerevisiae, 2004, pp.279, 33131~33138
172. Huss M, "Concanamycin A, the specific inhibitor of v-ATPases, binds to the v(o)subunit c", J Biol Chem, 277, pp.40544~40548 (2002)
173. Capurro M, "Glypican-3 binds to frizzled and plays a direct role in the stimulation of canonical Wnt signaling", J Cell Sci, 127(Pt 7), pp.1565~1575 (2014)
174. Guo M, "Glypican-3 : a new target for diagnosis and treatment of hepatocellular carcinoma", J Cancer, 11, pp.2008~2021 (2020)
175. Capurro MI, "Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling", Cancer Res, 65, pp.6245~6254 (2005)
176. Gao W, "Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy", Hepatology, 60, pp.576~587 (2014)